|
1
|
Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J,
Shan Z, Liu J, Tian H, Ji Q, et al: Prevalence of diabetes among
men and women in China. N Engl J Med. 362:1090–1101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu Y, Wang L, He J, Bi Y, Li M, Wang T,
Wang L, Jiang Y, Dai M, Lu J, et al: Prevalence and control of
diabetes in Chinese adults. JAMA. 310:948–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Testa MA, Gill J, Su M, Turner RR, Blonde
L and Simonson DC: Comparative effectiveness of basal-bolus vs.
premix analog insulin on glycemic variability and patient-centered
outcomes during insulin intensification in type 1 and type 2
diabetes: A randomized, controlled, crossover trial. J Clin
Endocrinol Metab. 97:3504–3514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wake N, Hisashige A, Katayama T, Kishikawa
H, Ohkubo Y, Sakai M, Araki E and Shichiri M: Cost-effectiveness of
intensive insulin therapy for type 2 diabetes: A 10-year follow-up
of the Kumamoto study. Diabetes Res Clin Pract. 48:201–210. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herman GA, Bergman A, Stevens C, Kotey P,
Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, et al:
Effect of single oral doses of sitagliptin, a dipeptidyl
peptidase-4 inhibitor, on incretin and plasma glucose levels after
an oral glucose tolerance test in patients with type 2 diabetes. J
Clin Endocrinol Metab. 91:4612–4619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenstock J, Aguilar-Salinas C, Klein E,
Nepal S, List J and Chen R: Effect of saxagliptin monotherapy in
treatment-naive patients with type 2 diabetes. Curr Med Res Opin.
25:2401–2411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Hong J, Chi J, Gu W, Ning G and
Wang W: Head-to-head comparison of dipeptidyl peptidase-IV
inhibitors and sulfonylureas - a meta-analysis from randomized
clinical trials. Diabetes Metab Res Rev. 30:241–256. 2013.
View Article : Google Scholar
|
|
8
|
Monami M, Cremasco F, Lamanna C,
Marchionni N and Mannucci E: Predictors of response to dipeptidyl
peptidase-4 inhibitors: Evidence from randomized clinical trials.
Diabetes Metab Res Rev. 27:362–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gabir MM, Hanson RL, Dabelea D, Imperatore
G, Roumain J, Bennett PH and Knowler WC: Plasma glucose and
prediction of microvascular disease and mortality: Evaluation of
1997 American Diabetes Association and 1999 World Health
Organization criteria for diagnosis of diabetes. Diabetes Care.
23:1113–1118. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lott JA and Turner K: Evaluation of
Trinder's glucose oxidase method for measuring glucose in serum and
urine. Clin Chem. 21:1754–1760. 1975.PubMed/NCBI
|
|
11
|
Bonora E, Targher G, Alberiche M,
Bonadonna RC, Saggiani F, Zenere MB, Monauni T and Muggeo M:
Homeostasis model assessment closely mirrors the glucose clamp
technique in the assessment of insulin sensitivity: Studies in
subjects with various degrees of glucose tolerance and insulin
sensitivity. Diabetes Care. 23:57–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tuerk PW, Mueller M and Egede LE:
Estimating physician effects on glycemic control in the treatment
of diabetes: Methods, effects sizes and implications for treatment
policy. Diabetes Care. 31:869–873. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C, Lv L, Yang Y, Chen D, Liu G, Chen
L, Song Y, He L, Li X, Tian H, et al: Glucose fluctuations in
subjects with normal glucose tolerance, impaired glucose regulation
and newly diagnosed type 2 diabetes mellitus. Clin Endocrinol
(Oxf). 76:810–815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cnop M, Igoillo-Esteve M, Hughes SJ,
Walker JN, Cnop I and Clark A: Longevity of human islet α-and
β-cells. Diabetes Obes Metab (13 Suppl 1). 39–46. 2011. View Article : Google Scholar
|
|
15
|
Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa
MB, Sayyed F, van de Laar L, Gunter JH, de Koning EJ, Walls GV,
Gray DW, et al: The long lifespan and low turnover of human islet
beta cells estimated by mathematical modelling of lipofuscin
accumulation. Diabetologia. 53:321–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szoke E, Shrayyef MZ, Messing S, Woerle
HJ, van Haeften TW, Meyer C, Mitrakou A, Pimenta W and Gerich JE:
Effect of aging on glucose homeostasis: Accelerated deterioration
of beta-cell function in individuals with impaired glucose
tolerance. Diabetes Care. 31:539–543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu HQ, Yang ZJ, Zhang B, Xiao JZ and Yang
WY: Ageing related changes of insulin secretion and insulin
sensitivity among normal glucose tolerance individuals in China.
Zhonghua Yi Xue Za Zhi. 92:1948–1953. 2012.(In Chinese). PubMed/NCBI
|
|
18
|
Basu R, Breda E, Oberg AL, Powell CC, Man
C Dalla, Basu A, Vittone JL, Klee GG, Arora P, Jensen MD, et al:
Mechanisms of the age-associated deterioration in glucose
tolerance: Contribution of alterations in insulin secretion, action
and clearance. Diabetes. 52:1738–1748. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saisho Y, Butler AE, Manesso E, Elashoff
D, Rizza RA and Butler PC: β-cell mass and turnover in humans:
Effects of obesity and aging. Diabetes Care. 36:111–117. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kushner JA: The role of aging upon β cell
turnover. J Clin Invest. 123:990–995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Butler AE, Janson J, Bonner-Weir S, Ritzel
R, Rizza RA and Butler PC: Beta-cell deficit and increased
beta-cell apoptosis in humans with type 2 diabetes. Diabetes.
52:102–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maclean N and Ogilvie RF: Quantitative
estimation of the pancreatic islet tissue in diabetic subjects.
Diabetes. 4:367–376. 1955. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bushhouse SA, Goetz FC, Jacobs DR Jr,
Bender AP, French LR, Oestreich PG and Geisser MS: C-peptide
response to meal challenge in nondiabetic and diabetic adults
living in Wadena, Minnesota. Diabetes Care. 15:1335–1347. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Geloneze B, de Oliveira Mda S, Vasques AC,
Novaes FS, Pareja JC and Tambascia MA: Impaired incretin secretion
and pancreatic dysfunction with older age and diabetes. Metabolism.
63:922–929. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stoffers DA, Kieffer TJ, Hussain MA,
Drucker DJ, Bonner-Weir S, Habener JF and Egan JM: Insulinotropic
glucagon-like peptide 1 agonists stimulate expression of
homeodomain protein IDX-1 and increase islet size in mouse
pancreas. Diabetes. 49:741–748. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Solis-Herrera C, Triplitt C,
Garduno-Garcia JJ, Adams J, DeFronzo RA and Cersosimo E: Mechanisms
of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin
when used alone or with metformin in type 2 diabetes: A
double-tracer study. Diabetes Care. 36:2756–2762. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rauch T, Graefe-Mody U, Deacon CF, Ring A,
Holst JJ, Woerle HJ, Dugi KA and Heise T: Linagliptin increases
incretin levels, lowers glucagon and improves glycemic control in
type 2 diabetes mellitus. Diabetes Ther. 3:102012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barzilai N, Guo H, Mahoney EM, Caporossi
S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM,
Goldstein BJ and Steinberg H: Efficacy and tolerability of
sitagliptin monotherapy in elderly patients with type 2 diabetes: A
randomized, double-blind, placebo-controlled trial. Curr Med Res
Opin. 27:1049–1058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teraguchi I, Imanishi T, Ozaki Y, Tanimoto
T, Ueyama M, Orii M, Shiono Y, Shimamura K, Ishibashi K, Yamano T,
et al: Acute-phase glucose fluctuation is negatively correlated
with myocardial salvage after acute myocardial infarction. Circ J.
78:170–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takihata M, Nakamura A, Tajima K, Inazumi
T, Komatsu Y, Tamura H, Yamazaki S, Kondo Y, Yamada M, Kimura M and
Terauchi Y: Comparative study of sitagliptin with pioglitazone in
Japanese type 2 diabetic patients: The COMPASS randomized
controlled trial. Diabetes Obes Metab. 15:455–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meyre D, Froguel P, Horber FF and Kral JG:
Comment on: Valette et al. Melanocortin-4 receptor mutations and
polymorphisms do not affect weight loss after bariatric surgery.
PLoS One. 9:e933242014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alexander CM, Landsman PB, Teutsch SM and
Haffner SM: Third National Health and Nutrition Examination Survey
(NHANES III); National Cholesterol Education Program (NCEP):
NCEP-defined metabolic syndrome, diabetes, and prevalence of
coronary heart disease among NHANES III participants age 50 years
and older. Diabetes. 52:1210–1214. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH,
Chen SJ, Yeh CM, Chen TJ, Lin SJ and Chiang CE: Sitagliptin and the
risk of hospitalization for heart failure: A population-based
study. Int J Cardiol. 177:86–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weir DL, McAlister FA, Senthilselvan A,
Minhas-Sandhu JK and Eurich DT: Sitagliptin use in patients with
diabetes and heart failure: A population-based retrospective cohort
study. JACC Heart Fail. 2:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
